Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4542MR)

This product GTTS-WQ4542MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ4542MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15186MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TA-650
GTTS-WQ6960MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ2780MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG-282
GTTS-WQ3383MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ966MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ2090MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ11953MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ14613MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SC0001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW